LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

43.05 1.65

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

43.05

Максимум

43.05

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+30.24% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-25M 3.2B
Предишно отваряне	41.4
Предишно затваряне	43.05

Настроения в новините

By Acuity

50%

141 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.02.2026 г., 23:55 ч. UTC

Пазарно говорене

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22.02.2026 г., 23:53 ч. UTC

Пазарно говорене

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22.02.2026 г., 23:53 ч. UTC

Пазарно говорене

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22.02.2026 г., 23:51 ч. UTC

Пазарно говорене

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22.02.2026 г., 23:35 ч. UTC

Пазарно говорене

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22.02.2026 г., 23:21 ч. UTC

Печалби

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22.02.2026 г., 23:20 ч. UTC

Печалби

Nickel Industries 2025 Operating Profit US$126.4 Million

22.02.2026 г., 23:19 ч. UTC

Печалби

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22.02.2026 г., 23:19 ч. UTC

Печалби

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22.02.2026 г., 23:18 ч. UTC

Печалби

Nickel Industries Won't Pay a Final Dividend

22.02.2026 г., 23:16 ч. UTC

Печалби

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22.02.2026 г., 21:35 ч. UTC

Печалби

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22.02.2026 г., 21:34 ч. UTC

Печалби

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22.02.2026 г., 21:34 ч. UTC

Печалби

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22.02.2026 г., 21:33 ч. UTC

Печалби

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22.02.2026 г., 21:33 ч. UTC

Печалби

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22.02.2026 г., 21:28 ч. UTC

Печалби

Ampol Final Dividend A$0.60/Share

22.02.2026 г., 21:28 ч. UTC

Печалби

Ampol FY Revenue A$31.37 Billion, Down 10%

22.02.2026 г., 21:28 ч. UTC

Печалби

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22.02.2026 г., 21:28 ч. UTC

Печалби

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21.02.2026 г., 14:31 ч. UTC

Придобивния, сливания и поглъщания

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21.02.2026 г., 05:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

20.02.2026 г., 23:12 ч. UTC

Придобивния, сливания и поглъщания

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20.02.2026 г., 22:12 ч. UTC

Печалби

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

20.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.02.2026 г., 21:23 ч. UTC

Печалби

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20.02.2026 г., 21:20 ч. UTC

Пазарно говорене

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20.02.2026 г., 21:01 ч. UTC

Придобивния, сливания и поглъщания

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20.02.2026 г., 20:38 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

30.24% нагоре

12-месечна прогноза

Среден 55 USD 30.24%

Висок 66 USD

Нисък 44 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

141 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.